Glucuronidation of the broad-spectrum antiviral drug arbidol by UGT isoforms (Q43452825)

23 November 2017

Glucuronidation of the broad-spectrum antiviral drug arbidol by UGT isoforms (English)

1 reference

23 November 2017

Jin-Hui Song

1

1 reference

23 November 2017

Zhong-Ze Fang

2

1 reference

23 November 2017

Liang-Liang Zhu

3

1 reference

23 November 2017

Yun-Feng Cao

4

1 reference

23 November 2017

Cui-Min Hu

5

1 reference

23 November 2017

Guang-Bo Ge

6

1 reference

23 November 2017

De-Wei Zhao

7

1 reference

23 November 2017

24 December 2012

1 reference

Journal of Pharmacy and Pharmacology

23 November 2017

1 reference

23 November 2017

65

1 reference

23 November 2017

4

1 reference

23 November 2017

521-527

1 reference

Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline?

23 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Drug glucuronidation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

UDP-glucuronosyltransferases and clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Metabolic map and bioactivation of the anti-tumour drug noscapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Pharmacogenomics of human UDP-glucuronosyltransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12014

21 January 2018

Identifiers

DOI

10.1111/JPHP.12014

1 reference

23 November 2017

1 reference